Development of a sensitive UPLC-ESI-MS/MS method for quantification of sofosbuvir and its metabolite, GS-331007, in human plasma: Application to a bioequivalence study

Journal of Pharmaceutical and Biomedical Analysis

Volumn 114, Issue , 2015, Pages 97-104

  Rezk, Mamdouh R ^a   Basalious, Emad B ^a   Karim, Iman A ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b Advanced Research Center (ARC)   (Egypt)

Author keywords

Bioequivalence; GS 331007; Plasma; Sofosbuvir; UPLC MS MS; Validation

Indexed keywords

ACETIC ACID ETHYL ESTER; ACETONITRILE; DRUG METABOLITE; FORMIC ACID; GS 331007; SOFOSBUVIR; UNCLASSIFIED DRUG; GS331007; URIDINE;

ACCURACY; ARTICLE; BIOEQUIVALENCE; DRUG BLOOD LEVEL; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; LIMIT OF QUANTITATION; MASS SPECTROMETRY; PRIORITY JOURNAL; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ANALOGS AND DERIVATIVES; AREA UNDER THE CURVE; BLOOD; CALIBRATION; CHEMISTRY; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIMIT OF DETECTION; METABOLISM; NORMAL HUMAN; PLASMA; PROCEDURES; QUALITY CONTROL; REPRODUCIBILITY; TANDEM MASS SPECTROMETRY;

AREA UNDER CURVE; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; HEALTHY VOLUNTEERS; HUMANS; LIMIT OF DETECTION; PLASMA; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; SOFOSBUVIR; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; URIDINE;

EID: 84930619822     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2015.05.006     Document Type: Article

References (14)

1. Sofia M.J., Bao D., Chang W., Du J., Nagarathnam D., Rachakonda S., Reddy P.G., Ross B.S., Wang P., Zhang H.R., Bansal S., Espiritu C., Keilman M., Lam A.M., Steuer H.M., Niu C., Otto M.J., Furman P.A. Discovery of a beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J. Med. Chem. 2010, 53:7202-7218.
2. Eldrup A.B., Prhavc M., Brooks J., Bhat B., Prakash T.P., Song Q., Bera S., Bhat N., Dande P., Cook P.D., Bennett C.F., Carroll S.S., Ball R.G., Bosserman M., Burlein C., Colwell L.F., Fay J.F., Flores O.A., Getty K., LaFemina R.L., Leone J., MacCoss M., McMasters D.R., Tomassini J.E., Von Langen D., Wolanski B., Olsen D.B. Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication. J. Med. Chem. 2004, 47:5284-5297.
3. Berden F.A., Kievit W., Baak L.C., Bakker C.M., Beuers U., Boucher C.A., Brouwer J.T., Burger D.M., van Erpecum K.J., van Hoek B., Hoepelman A.I., Honkoop P., Kerbert-Dreteler M.J., de Knegt R.J., Koek G.H., van Nieuwkerk C.M., van Soest H., Tan A.C., Vrolijk J.M., Drenth J.P. Dutch guidance for the treatment of chronic hepatitis C virus infection in a new therapeutic era. Neth. J. Med. 2014, 72:388-400.
4. Cholongitas E., Papatheodoridis G.V. Sofosbuvir: a novel oral agent for chronic hepatitis C. Ann. Gastroenterol. 2014, 27:331-337.
5. Cha A., Budovich A. Sofosbuvir: a new oral once-daily agent for the treatment of hepatitis C virus infection. Pharm. Ther. 2014, 39:345-352.
6. FDA, Guidance for Industry: Bioanalytical Method Validation, US Department of Health and Human Services, Guidance for Industry: Bioanalytical Method Validation, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CV) (2001).
7. Zimmer D. New US FDA draft guidance on bioanalytical method validation versus current FDA and EMA guidelines: chromatographic methods and ISR. Bioanal. 2014, 6:13-19.
8. Dams R., Huestis M.A., Lambert W.E., Murphy C.M. Matrix effect in bio-analysis of illicit drugs with LC-MS/MS: influence of ionization type, sample preparation, and biofluid. J. Am. Soc. Mass Spectrom. 2003, 14:1290-1294.
9. Van Eeckhaut A., Lanckmans K., Sarre S., Smolders I., Michotte Y. Validation of bioanalytical LC-MS/MS assays: evaluation of matrix effects. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2009, 877:2198-2207.
10. De Nardi C., Bonelli F. Moving from fast to ballistic gradient in liquid chromatography/tandem mass spectrometry pharmaceutical bioanalysis: matrix effect and chromatographic evaluations. Rapid Commun. Mass Spectrom. 2006, 20:2709-2716.
11. Sauvage F.L., Gaulier J.M., Lachatre G., Marquet P. A fully automated turbulent-flow liquid chromatography-tandem mass spectrometry technique for monitoring antidepressants in human serum. Ther. Drug Monit. 2006, 28:123-130.
12. Alberti A., Piovesan S. The evolution of the therapeutic strategy in hepatitis C: features of sofosbuvir and indications. Dig. Liver Dis. 2014, 46(Suppl. 5):S174-S178.
13. Sathe P., Venitz J., Lesko L. Evaluation of truncated areas in the assessment of bioequivalence of immediate release formulations of drugs with long half-lives and of Cmax with different dissolution rates. Pharm. Res. 1999, 16:939-943.
14. Rezk M.R., Badr K.A. Development, optimization and validation of a highly sensitive UPLC-ESI-MS/MS method for simultaneous quantification of amlodipine, benazeprile and benazeprilat in human plasma: application to a bioequivalence study. J. Pharm. Biomed. Anal. 2014, 98:1-8.